首页> 外国专利> COMPOSITIONS AND METHODS OF TREATING NO-OPTION CRITICAL LIMB ISCHEMIA (CLI)

COMPOSITIONS AND METHODS OF TREATING NO-OPTION CRITICAL LIMB ISCHEMIA (CLI)

机译:治疗非选择性临界肢体缺血(CLI)的组合物和方法

摘要

The present invention provides methods for treating critical limb ischemia (CLI), including increasing wound healing, decreasing wound size, increasing survival-free amputation, preventing amputation, preventing or delaying de novo gangrene, increasing survival probability, and preventing or delaying death, in subjects who prevent a vascular occlusion that cannot be resolved by using a standard method of revascularization, i.e. a subject with no-option CLI. Methods of the invention include administering to a subject with no-option CLI an isolated cell composition for tissue repair comprising a mixed population of cells of hematopoietic, mesenchymal and endothelial lineage, wherein the viability of said cells is at least 80% and the composition contains: a) about 5-75% viable CD90+ cells with the remaining cells in said composition being CD45+; b) less than 2 g/ml of bovine serum albumin; c) less than 1 g/ml of a enzymatically active harvest reagent; and d) substantially free of mycoplasma, endotoxin, and microbial contamination.
机译:本发明提供了治疗严重肢体缺血(CLI)的方法,包括增加伤口愈合,减小伤口大小,增加无生存力的截肢,预防截肢,预防或延迟新生坏疽,增加生存率以及预防或延迟死亡。预防无法通过使用标准血运重建方法解决的血管阻塞的受试者,即无选择CLI的受试者。本发明的方法包括向具有非选择性CLI的受试者施用用于组织修复的分离的细胞组合物,其包含造血,间充质和内皮细胞谱系的混合细胞群,其中所述细胞的生存力至少为80%,并且所述组合物包含:a)约5-75%的存活CD90 +细胞,所述组合物中的剩余细胞为CD45 +; b)牛血清白蛋白低于2 g / ml; c)低于1 g / ml的酶促活性收获剂; d)基本上没有支原体,内毒素和微生物污染。

著录项

  • 公开/公告号EP2579882A1

    专利类型

  • 公开/公告日2013-04-17

    原文格式PDF

  • 申请/专利权人 AASTROM BIOSCIENCES INC.;

    申请/专利号EP20110726304

  • 发明设计人 BARTEL RONNDA;WATLING SHARON;

    申请日2011-06-10

  • 分类号A61K35;A61K35/14;C12N5;A61P9/10;

  • 国家 EP

  • 入库时间 2022-08-21 16:30:05

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号